Navigation Links
ImaRx Therapeutics Transitions Business Strategy
Date:1/30/2008

Focuses on Commercial Product Urokinase and Evaluates Strategic

Alternatives for SonoLysis(TM) Development Program

TUCSON, Ariz. Jan. 30 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) announced today that it will emphasize growing the market for urokinase in contrast to its previous focus on developing SonoLysis.

The reprioritization of additional value-creating opportunities for urokinase was made possible by the Company's recently signed letter of intent with Microbix Biosystems which provides for manufacture of a long term urokinase supply and will allow the company to explore additional therapeutic applications for the product.

Urokinase, the Company's first commercially available FDA approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs.

Following a comprehensive review of its commercial and development programs as well as external market conditions ImaRx's Board of Directors and management have determined that it is in the best interests of the Company to adjust its emphasis to focus on commercialization of urokinase.

At the same time the company will explore strategic alternatives for continued pursuit and financing of its SonoLysis program-the Company's clinical-stage development program utilizing its proprietary microbubbles and ultrasound to treat ischemic stroke.

This shift of business strategy to place greater emphasis on urokinase is expected to help the Company preserve existing capital and focus its efforts on growing urokinase product sales while maintaining shareholder participation in the SonoLysis opportunity.

"By focusing on broader comm
'/>"/>

SOURCE ImaRx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
4. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
5. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
8. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
9. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
10. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
11. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
(Date:8/21/2014)... , Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and medical ... investor conferences in September: , September 4, 2014 ... , NY at 12:50 p.m. ET , September 8, ... New York , NY at 1:25 p.m. ET ...
(Date:8/21/2014)... 21, 2014  Armada Health Care (Armada), the ... is pleased to announce an agreement with Aurora ... of innovative specialty pharmacy patient program offerings. The ... management services to specialty patients via Armada,s proprietary ... Aurora will use the OTM platform as its ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3
... 23 May 2007 - The antidepressant duloxetine,hydrochloride was ... who did not respond, or responded only,partially, to ... of whether those patients were,switched from an SSRI ... presented today at the American Psychiatric,Association’s 160 th ...
... /PRNewswire/ -- With enormous,investments and the success ... need to develop effective strategies for,communicating clinical ... planning and execution will gain a significant,advantage ... and consulting firm Best Practices, LLC,successful companies ...
Cached Medicine Technology:In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
(Date:8/22/2014)... (PRWEB) August 22, 2014 ItsHot.com, a ... now offering 60-80% off on its range of beautiful ... the purchase of Gold Hearts 14K White Rose Gold ... a discount of 77%. Previously priced at $3,715.00, ... $859.00. The item code of this mesmerizing pendant embedded ...
(Date:8/22/2014)... August 22, 2014 Key West Health ... experts revealed their much anticipated study results of the ... today and released an accompanying infographic on their website. ... can have a major impact on the skin and ... and more. , When asked how they determined the ...
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” ... Luciana, is finding it challenging to stay on top of ... of hundreds of students, so the editing of the episodes ... completed, and she recently entered it into the festival circuit. ... her husband, actor/screenwriter Gregory Graham , the aging and ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Until now, those ... standard crutches or walkers to keep mobile. Thanks to an ... made much more effective. , He developed a prototype for ... an injured leg or foot but provide comfort and reduce ... to different heights, it is also convenient and easy to ...
(Date:8/22/2014)... August 22, 2014 Braverman Eye Center ... Fort Lauderdale at the most affordable fee. They are ... through their advanced Lasik treatments. LASIK is a highly ... Braverman Eye Center has been delivering successful LASIK solutions ... a glasses-free and contact lenses-free life with the help ...
Breaking Medicine News(10 mins):Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2
... Tenn., Feb. 13 Two laptop computers,are missing ... The dual-password protected laptops were used on ... Lifeblood,s blood,donors, including names, contact information, blood type, ... The organization is notifying all of the ...
... Corporation,(NYSE: SYK ) today announced that its Board ... $750 million of its common stock. Purchases may,be made ... privately negotiated,transactions or otherwise. The manner, timing and amount ... based on their evaluation of,market conditions, stock price and ...
... can lead to higher levels of severe post-natal depression (PND) and ... published in the February issue of Journal of Clinical Nursing. , ... Universite Nancy 2, France, found that just under a third of ... had PND. , Nine per cent of the women in ...
... Sun Busters(R), the swim,wear line for children that has ... protection now sports a new feature -- The Skin ... proud,to announce that they have met the high standards ... of 50+. UPF is a similar concept to SPF;,however ...
... Scientists in Switzerland are uncovering new clues about how cancer ... by studying stem cells, blank cells that have the potential ... scientists in UK have made a breakthrough in understanding the ... lymphoblastic leukaemia (ALL). The research should lead to less aggressive ...
... Procter & Gamble Company,(NYSE: PG ) today announced the following organizational ... will retire on June 1, 2008 after ... deputy general counsel, will succeed Mr. Johnson ... vice president - finance and accounting, global ...
Cached Medicine News:Health News:Two Laptop Computers Missing From Lifeblood's Main Office 2Health News:Male births are more likely to reduce quality of life and increase severe post-natal depression 2Health News:Male births are more likely to reduce quality of life and increase severe post-natal depression 3Health News:Sun Busters(R) Now Sports The Skin Cancer Foundation's Seal of Recommendation 2Health News:Sun Busters(R) Now Sports The Skin Cancer Foundation's Seal of Recommendation 3Health News:Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia 2Health News:Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia 3Health News:Procter & Gamble Announces Organizational Changes 2
Infusion Cannula, 2.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
Medicine Products: